What’s the real promise of the spadin‑derived PE 22‑28 antidepressant?

Posted by kayla_s in Research & News - 1 points, 2 comments.

I just read the latest preclinical paper on PE 22‑28, the spadin‑derived peptide that blocks TREK‑1 channels. org/peptides/pe-22-28). For me, it’s exciting because it’s a different mechanism than the usual SSRIs, but the human data are still a long way off.

I’m curious what the community thinks about chasing a peptide that’s only got animal evidence so far, do you see a realistic path to human trials, or are we looking at a case of hype over early data? I’ve used noopept and adamax together for mood boosts, and the response was mild; would a TREK‑1 blocker change the game, or could it bring unforeseen side effects? What do you all think?

Comments

• reads_lifter: I’ve seen a few people jump on any peptide that shows antidepressant activity in mice, and it’s easy to get swept up in the hype. For me the noopept + adamax combo felt like a tweak, not a revolution – a little brighter focus but nothing that changed my mood that much. If a TREK‑1 blocker really works in humans it could be a fresh angle, but the same mice studies that show benefits also show seizure‑like spikes and trouble with blood pressure when the channel is fully shut down. I worry that “b
• kayla_s: Thanks for the heads‑up about the seizure‑like spikes and BP swings, reads_lifter. I’ve been just doing the 3 mg Noopept/2 mg Adamax combo for a couple of months with only a faint lift in focus and no mood change, so I totally get the “tweak” vibe you mentioned. If a TREK‑1 blocker does hit humans, I_FACTORY wonder if we can titrate it slowly to avoid the channel‐overkill and a trade‑off in blood pressure. Would you tweak the dose a bit or keep the spike‑risk in mind?

Community discussion - research and educational context only. Not medical advice.